Equities

Kidswell Bio Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4584:TYO

Kidswell Bio Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)252.00
  • Today's Change-6.00 / -2.33%
  • Shares traded668.00k
  • 1 Year change+117.24%
  • Beta1.2742
Data delayed at least 15 minutes, as of Feb 13 2026 00:32 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

  • Revenue in JPY (TTM)6.61bn
  • Net income in JPY281.24m
  • Incorporated2001
  • Employees37.00
  • Location
    Kidswell Bio CorpNihombashi Life Science Bldg. 33-8-3, Nihombashihon-choCHUO-KU 103-0023JapanJPN
  • Phone+81 362229547
  • Fax+81 362229548
  • Websitehttps://www.kidswellbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TMS Co Ltd0.00-670.20m6.50bn18.00--2.17-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
Cyfuse Biomedical KK-100.00bn-100.00bn6.75bn21.00--2.27----------298.18------------------------5.80--0.3038---10.91---48.03------
Noile-Immune Biotech Inc7.14m-782.47m6.76bn25.00--1.64--945.69-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
PRISM BioLab Co Ltd677.33m-833.70m7.17bn35.00--2.64--10.58-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
Tsubota Laboratory Inc973.21m-172.89m7.25bn17.00--5.61--7.45-6.79-6.7937.6150.080.47330.67264.0057,247,590.00-8.410.1041-12.170.151780.2771.43-17.760.22162.89--0.05860.00101.4925.17132.08132.7026.42--
OncoTherapy Science, Inc.784.25m-881.65m7.46bn47.00--3.52--9.51-2.93-2.932.605.680.42248.388.7216,686,090.00-47.48-63.66-56.22-77.433.63-0.3852-112.42-184.758.13-832.790.0043--22.9318.8636.71---70.80--
Linical Co Ltd9.87bn-1.19bn7.84bn598.00--1.18--0.7946-52.52-52.52437.00267.760.6226--3.6916,505,640.00-7.482.59-13.504.1921.6129.24-12.023.74----0.258477.26-15.20-0.9283-259.37---42.014.24
Medinet Co Ltd810.29m-1.36bn7.97bn107.00--2.10--9.84-5.15-5.153.0614.270.162814.023.357,572,813.00-27.37-22.42-28.82-23.6413.5417.68-168.10-173.5915.28--0.00--5.440.6867-6.67--10.06--
Chiome Bioscience Inc593.29m-982.78m8.20bn47.00--7.20--13.81-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Chordia Therapeutics Inc0.00-1.46bn8.68bn20.00--3.64-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn9.09bn24.00--5.04--8,190.95-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Nano Holdings Inc141.92m-757.17m10.91bn20.00--3.91--76.90-10.69-10.692.0136.620.03598.1716.767,095,800.00-18.65-23.68-21.92-25.3772.6482.69-533.54-746.834.10--0.00---19.92-27.80-7.10------
Kidswell Bio Corp6.61bn281.24m12.90bn37.0039.555.8945.771.956.576.57147.4144.111.264.316.10178,604,300.005.38-16.7510.76-27.0632.3947.464.26-28.291.37--0.3416--109.0336.3798.51--27.20--
Data as of Feb 13 2026. Currency figures normalised to Kidswell Bio Corp's reporting currency: Japanese Yen JPY

Institutional shareholders

2.10%Per cent of shares held by top holders
HolderShares% Held
Heights Capital Management, Inc.as of 14 Aug 2025947.19k1.91%
Simplex Asset Management Co., Ltd.as of 08 Jan 202687.30k0.18%
American Century Investment Management, Inc.as of 08 Jan 20265.50k0.01%
Dimensional Fund Advisors LPas of 08 Jan 2026300.000.00%
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.